Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Problems with risk-sharing study must not deter future collaborations

This article was originally published in Scrip

Executive Summary

“A costly failure” and “a fiasco” are just two of the epithets that have been used to describe the UK’s first-ever risk-sharing scheme to evaluate the long-term cost-effectiveness of two multiple sclerosis therapies, β-interferon and glatiramer acetate. Or as one commentator put it: “This may well be the most expensive publicly-funded ongoing health-related study in the UK, and probably anywhere, ever.”


Related Content

Stockwatch: What Links Actimmune And Vertex’s Event Horizon?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts